Latest News

Press release

| News, USA

Immatics Announces Business Combination with Arya Sciences Acquisition Corp., […]

Read more

Press release

| News, USA

Immatics and GSK Partner to Develop Novel Adoptive Cell Therapies

Read more

Press release

| News, USA

Immatics and Celgene Enter Strategic Collaboration to Develop Novel Adoptive […]

Read more

Product Pipeline

Immatics has identified and characterized a trove of intracellular tumor targets for immunotherapeutic development. We use this knowledge together with our technologies to define true targets, distinct molecular barcodes that identify the tumor cell. This gives us a drug discovery advantage that we leverage for our own proprietary pipeline of Adoptive Cell Therapies and TCR Bispecifics and for our collaborations with world-leading partners.

Our pipeline

Products and Technologies

Adoptive Cell Therapies

Immatics is developing engineered Adoptive Cell Therapies (ACTengine®) directed against various targets relevant in a broad range of cancers and is advancing next-generation ACT approaches including allogeneic cell therapies (ACTallo®) and a novel ultra-personalized approach to immunotherapy.

About ACT

TCER™

Immatics’ TCR Bispecifics (TCER™) are Immatics’ off-the-shelf biologics designed to leverage the body’s immune system by redirecting and activating the T cell response towards cancer cells.

About Bispecific T-Cell Receptor molecules

Discovery Platforms

A unique strength is Immatics’ two proprietary technology discovery platforms: XPRESIDENT® and XCEPTOR™. These platforms enable identification of true targets and development of the right TCRs.

About our technologies

Our Collaborators

GSK

GSK and Immatics Enter Strategic Collaboration to Develop Novel Adoptive Cell Therapies Targeting Multiple Cancer Indications, Feb 20, 2020.

Learn more

Bristol-Myers Squibb

Immatics and Celgene, a Bristol-Myers Squibb Company, Enter Strategic Collaboration to Develop Novel Adoptive Cell Therapies, Aug 28, 2019.

Learn more

Genmab

Immatics Enters into a Strategic Partnership with Genmab to Develop Next Generation Bispecific Cancer Immunotherapies, Jul 12, 2018.

Learn more

Amgen

Amgen and Immatics Enter Strategic Collaboration to Develop Novel Bispecific Cancer Immunotherapies, Jan 09, 2017.

Learn more

MD Anderson

Immatics and MD Anderson Announce Launch of Immatics US, Inc., to Develop Multiple T-cell and TCR-based Adoptive Cellular Therapies, Aug 26, 2015.

Learn more

MorphoSys

MorphoSys and Immatics Biotechnologies Enter Strategic Alliance in Immuno-oncology, Aug 25, 2015.

Learn more
We use cookies to ensure that we give you the best experience on our website.